Trial Profile

Clinical Trial for the Safety and Efficacy of CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CD70 CAR-T cell therapy-Yake Biotechnology (Primary)
Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma
Focus Adverse reactions

Most Recent Events

26 Oct 2021 Planned initiation date (estimated date of first participant enrollement) changed from 15 Jan 2021 to 18 Nov 2021.
26 Oct 2021 Status changed from not yet recruiting to recruiting.
18 Dec 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com